**Question for written answer E-000180/2021**
**to the Commission**
Rule 138
**Krzysztof Hetman** (PPE)

Subject: Agreements with pharmaceutical companies on COVID-19 vaccines

To date, the Commission has approved the use of two COVID-19 vaccines in the European Union: On 21 December 2020, following positive recommendations from the European Medicines Agency, the use of a vaccine produced by BioNTech and Pfizer was authorised, and a vaccine manufactured by Moderna was authorised for use on 6 January 2021.

Bearing in mind that the two authorisations were granted on the basis of very solid arguments concerning the safety, efficacy and quality of the vaccines, how does the agreement between the two pharmaceutical companies and the Commission determine issues of liability for long-term side-effects that could potentially arise in vaccinated people? Will the manufacturers, i.e. the above pharmaceutical companies, be held liable in this respect?